Effect of oral semaglutide on hepatic fibrosis of type 2 diabetes patients with NAFLD

Effect of oral semaglutide on hepatic fibrosis of type 2 diabetes patients with NAFLD - Effect of oral semaglutide on hepatic fibrosis of type 2 diabetes patients with NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046994

Enrollment

Registered

2022-03-03

Start date

2022-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes patients with NAFLD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with suspected NAFLD by abdominal echo (2)BMI higher than 25 kg/m2 (3)Taking alcohol less than 30g/day(men) and 20g/day(women) (4)Switching from DPP-4 inhibitor to oral semaglutide (5)Patients who consented to this study

Exclusion criteria

Exclusion criteria: (1) Diabetes other than type 2 diabetes (2) Taking thiazolidine drugs (3) History of use of other GLP-1 receptor agonists (4) Patients diagnosed with liver diseases other than NAFLD such as viral hepatitis and autoimmune hepatitis (5) Allergies to semaglutide (6) Diabetic ketoacidosis, diabetic coma or precoma, type 1 diabetes (7) Serious conditions such as acute infections and surgery (8) Patients judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
change in FIB4 index at 6 months from baseline	—

Secondary

Measure	Time frame
change in NFS,M2BPGi,tryptophan and tryptophan metabolites and the other various parameters at 6 months from baseline	—

Countries

Japan

Contacts

Public ContactRieko Kosugi

Shizuoka General Hospital Center for Diabetes, Endocrinology and Metabolism,

fwkh7040spring@yahoo.co.jp0542476111

Outcome results